Why AstraZeneca plc could have a major impact on your investment performance

AstraZeneca plc (LON: AZN) could be about to deliver vastly-improved financial performance.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a hugely challenging few years for AstraZeneca (LSE: AZN). The pharmaceutical company has experienced a loss of patents on a number of key drugs. This has allowed generic competition to eat away at its sales, which has caused a severe fall in its profitability. In fact, its bottom line has declined by 37% in the last four years. Although it is set to fall again this year, a brighter future may be ahead for the business. As such, it could be worth buying right now.

A changing business

Under its current management team, AstraZeneca has pursued a strategy of acquisitions. This has strengthened its drug pipeline and created a business which has growth potential in the long run. The acquisitions it has made have been a sound use of cash, with it focusing on areas such as diabetes that could prove to be a major growth area in future years.

Looking ahead, more acquisitions could be on the cards. The company has a sound balance sheet and excellent cash flow. Together, they mean that it could increase significantly in size to accommodate other businesses. This could not only boost its financial performance, but also improve investor sentiment in order to generate a higher rating for its shares.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Investment opportunity

After a number of years of falling profitability, AstraZeneca is expected to record positive earnings growth in 2018. While an anticipated rise in earnings of 2% next year is hardly exceptional, it would represent tangible progress for the business. This in itself could mean the stock is worthy of a higher price-to-earnings (P/E) ratio than its current 15.5. And with a number of other pharmaceutical companies having significantly higher ratings, it would not be difficult to justify a higher valuation.

Higher profitability is also likely to lead to greater dividend payments over the medium term. Currently, the stock yields 4.9% from a dividend which is covered 1.3 times by profit. A growing dividend could act as a further positive catalyst and mean that the company’s total returns improve in future. As such, now could be the perfect time to buy it.

Repositioning

Also offering upside potential is banking and financial services company Secure Trust Bank (LSE: STB). It reported encouraging results on Tuesday which show that the changes it is making to its business are starting to bear fruit. For example, its profit before tax increased by 11%, while its overall loan book increased by 34% and customer deposits increased by 27%.

The company is expected to report a rise in its bottom line of 9% in the current year, followed by further growth of 33% next year. Despite this, it trades on a price-to-earnings growth (PEG) ratio of just 0.3, which suggests it offers a wide margin of safety. And with a dividend yield of 4.4% from a payout which is covered 1.9 times by profit, its income prospects continue to be robust. After a 17% share price fall in the last year, it could be worth buying.

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Tesla building with tesla logo and two teslas in front
Investing Articles

Tesla stock is down. But it may be far from out!

Tesla stock has crashed this year but its long-term record of value creation is outstanding. So, could this be a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

£3k in savings? That’s plenty to start buying shares and earning passive income!

Christopher Ruane explores how a stock market newcomer could start buying shares with a few thousand pounds and an appetite…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

5 passive income techniques of stock market millionaires

Christopher Ruane details a handful of approaches many successful stock market investors use to grow their passive income streams.

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

Down 42% in a year, here’s why Aston Martin shares could keep falling

Aston Martin shares have destroyed vast amounts of shareholder value since the company listed in 2018. Are they now a…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

FTSE shares: a once in a blue moon chance to get rich?

Christopher Ruane explains why he thinks hunting for blue-chip FTSE bargains in the current market could help an investor build…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

4 stocks Fools have bought for growth and dividends

Sometimes, an investor doesn’t have to make the choice between buying a growth stock or dividend shares! Some investments offer…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Is there no limit to how high Rolls-Royce shares might go?

Christopher Ruane sees some reasons Rolls-Royce shares could continue pushing upwards. But is he persuaded enough about the potential value…

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

How much could £20k in a Stocks and Shares ISA be worth in 2030?

UK investors have enjoyed spectacular returns in their Stocks and Shares ISA's over the past five years. Would could the…

Read more »